Spring til hovednavigation Spring til søgning Spring til hovedindhold

Certolizumab-pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: clinical and radiographic 48-weeks results of the investigator-initiated randomized NORDSTAR trial.

  • Mikkel Østergaard
  • , R Van Vollenhoven
  • , Anna Rudin
  • , Merete Lund Hetland
  • , D. Nordström
  • , Michael Nurmohamed
  • , B. Gudbjørnsson
  • , Lykke Midtbøll Ørnbjerg
  • , Pernille Bøyesen
  • , I Olsen
  • , Kristina Lend
  • , K Hørslev-Petersen
  • , T Uhlig
  • , Tuulikki Sokka-Isler
  • , Gerdur Gröndal
  • , Simon Krabbe
  • , Joakim Lindqvist
  • , Inger Gjertsson
  • , Daniel Erik Glinatsi
  • , Meliha C Kapetanovic
  • Anna-Birgitte Aga, Francesca Faustini, Pinja Parmanne, T Lorenzen, Giovanni Cagnotto, Johan Back, Oliver Hendricks, Daisy Vedder, Tuomas Rannio, Emma Grenholm, Hanne Merete Lindegaard, Maud-Kristine Aga Ljosa, Elisabeth Brodin, A Soderbergh, Milad Rizk, E Hermansson, Line Uhrenholt, Per Larsson, Søren Andreas Just, G Bakland, D. Stevens, TB Laurberg, E.A. Haavardsholm, Jon Lampa
OriginalsprogEngelsk
Publikationsdato2022
StatusUdgivet - 2022
BegivenhedEULAR 2022 - Copenhagen
Varighed: 1 jun. 20224 jun. 2022

Konference

KonferenceEULAR 2022
ByCopenhagen
Periode01/06/202204/06/2022

Citationsformater